NorthStrive Biosciences Advances to Phase III of AI-Driven Drug Discovery Program Toward Validation of Multiple Potential Drug Compounds & Discoveries

Core Viewpoint - NorthStrive Biosciences Inc. has initiated Phase III of its AI Development Program in collaboration with Yuva Biosciences, marking a significant advancement in developing therapies for obesity and related metabolic conditions [1][2]. Group 1: Phase III Development - Phase III aims to build on Phase II results, where YuvaBio utilized its MitoNova™ AI platform to identify small-molecule candidates that promote mitochondrial health and muscle preservation, particularly relevant for patients using GLP-1 receptor agonists [2][7]. - The Phase III program will generate biological data on AI-selected compounds, including cytotoxicity screening and ANT1 expression testing, and is expected to last approximately 6 to 9 weeks [2][7]. Group 2: Company Background - Yuva Biosciences, Inc. focuses on leveraging mitochondrial science and AI to develop therapeutic candidates targeting aging-related and metabolic pathways, utilizing its proprietary MitoNova™ platform [3]. - NorthStrive Biosciences Inc. specializes in developing aesthetic medicines, with its lead asset, EL-22, designed to address muscle preservation during weight loss treatments [4]. - PMGC Holdings Inc. is a diversified holding company managing a portfolio of subsidiaries, including NorthStrive Biosciences, and is committed to exploring growth opportunities across various sectors [5].